IE00B4Q5ZN47 - Common Stock - After market: 157.77 0 (0%)
Their shares may be down, but their sales are up.
These three companies should deliver inflation-busting long-term growth.
These stocks have plenty of room to run.
Jazz Pharmaceuticals (JAZZ) and Zymeworks (ZYME) announced 84% overall survival for zanidatamab, an experimental therapy for gastroesophageal adenocarcinoma. Read the full story here.
Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease...
There are still plenty of growth opportunities left for these businesses.
These stocks look cheap if you take a long-term view.
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 41st Annual J.P. Morgan...
Don't give up on this sector too quickly.
These biotechs are far from having achieved their full potential.
These mid-cap biotechs are solid long-term choices.
Revenue prospects look promising for both of these biotech companies.
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced that Jazz has exercised its option to continue with...
Axsome's revenue story is just getting started.
Jazz Pharmaceuticals (JAZZ) traded higher pre-market Friday after Goldman Sachs upgraded the Ireland-based biopharma to Buy from Neutral. Read the full story here.
These biotech players beat the bear market this year.
Here are three winners in the making.
Avadel Pharmaceuticals (AVDL) stock rose ~13% on Wednesday after Jefferies Financial upgraded the shares to Buy from Hold on opportunity of taking market share from Jazz...
Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that.
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six company-sponsored Epidiolex® (cannabidiol) oral solution presentations,...
These stocks are undervalued considering their long-term growth potential.
The next year should be a busy one for this drugmaker.
The CBD industry is growing at a high 20% CAGR and is expected to more than triple in size over the next 6 to 7 years, that's a budding opportunity.